To confirm these findings, we used a CXCR7 specific antibody, 11G8, to neutralize surface CXCR7, as well as a small molecule antagonist, CCX771, to block CXCR7 in HBMECs and measured subsequent cellular adhesion to matrigel and glioma cells. Here, ACKR3 is linked to central nervous system cancer.